JP2024502471A5 - - Google Patents

Info

Publication number
JP2024502471A5
JP2024502471A5 JP2023541519A JP2023541519A JP2024502471A5 JP 2024502471 A5 JP2024502471 A5 JP 2024502471A5 JP 2023541519 A JP2023541519 A JP 2023541519A JP 2023541519 A JP2023541519 A JP 2023541519A JP 2024502471 A5 JP2024502471 A5 JP 2024502471A5
Authority
JP
Japan
Prior art keywords
dose
pharmaceutical composition
antagonist
composition according
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023541519A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024502471A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/011643 external-priority patent/WO2022150605A1/en
Publication of JP2024502471A publication Critical patent/JP2024502471A/ja
Publication of JP2024502471A5 publication Critical patent/JP2024502471A5/ja
Pending legal-status Critical Current

Links

JP2023541519A 2021-01-08 2022-01-07 ピーナッツアレルギーを治療するための方法およびil-4rアンタゴニストを投与することによってピーナッツアレルゲン特異的免疫療法を増強する方法 Pending JP2024502471A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163135238P 2021-01-08 2021-01-08
US63/135,238 2021-01-08
EP21315241.6 2021-11-10
EP21315241 2021-11-10
PCT/US2022/011643 WO2022150605A1 (en) 2021-01-08 2022-01-07 Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist

Publications (2)

Publication Number Publication Date
JP2024502471A JP2024502471A (ja) 2024-01-19
JP2024502471A5 true JP2024502471A5 (cg-RX-API-DMAC7.html) 2025-01-15

Family

ID=80034850

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023541519A Pending JP2024502471A (ja) 2021-01-08 2022-01-07 ピーナッツアレルギーを治療するための方法およびil-4rアンタゴニストを投与することによってピーナッツアレルゲン特異的免疫療法を増強する方法

Country Status (9)

Country Link
US (1) US20220220211A1 (cg-RX-API-DMAC7.html)
EP (1) EP4274609A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024502471A (cg-RX-API-DMAC7.html)
KR (1) KR20230130681A (cg-RX-API-DMAC7.html)
AU (1) AU2022206434A1 (cg-RX-API-DMAC7.html)
CA (1) CA3204515A1 (cg-RX-API-DMAC7.html)
IL (1) IL304240A (cg-RX-API-DMAC7.html)
MX (1) MX2023007945A (cg-RX-API-DMAC7.html)
WO (1) WO2022150605A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CN118286417A (zh) 2012-09-07 2024-07-05 瑞泽恩制药公司 以il-4r拮抗剂治疗特应性皮炎的方法
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法
PT3110848T (pt) 2014-09-24 2024-03-05 Regeneron Pharma Métodos para tratamento de infeção cutânea por administração de um antagonista do il-4r
KR102872485B1 (ko) 2016-09-01 2025-10-20 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법
KR20210143246A (ko) 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
JP7736667B2 (ja) 2019-08-05 2025-09-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Il-4rアンタゴニストを投与することによるアトピー性皮膚炎の治療方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2990420T (pt) 2000-05-26 2017-03-16 Immunex Corp Uso de anticorpos de recetor de interleucina-4 e composições dos mesmos
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
UA93653C2 (ru) 2003-11-07 2011-03-10 Иммунекс Корпорейшн Выделенное антитело, kotopoe специфически связывается c человеческим рецептором il-4 (il-4r)
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CA2664343C (en) 2006-10-02 2016-04-26 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
MX366337B (es) 2010-10-06 2019-07-05 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r).
WO2014159609A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
MX2015010315A (es) 2013-03-14 2016-04-13 Aimmune Therapeutics Inc Fabricacion de formulaciones de mani para desensibilizacion oral.
TWI755763B (zh) * 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
CN107474134B (zh) 2016-06-08 2021-07-27 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
KR102872485B1 (ko) * 2016-09-01 2025-10-20 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법
EP4406975A3 (en) * 2018-06-14 2024-11-13 Ajinomoto Co., Inc. Compound having affinity substance to antibody and bioorthogonal functional group, or salt thereof
KR102330596B1 (ko) 2018-11-09 2021-11-26 아주대학교산학협력단 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도
KR20210143246A (ko) * 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
US11504426B2 (en) * 2019-08-05 2022-11-22 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist

Similar Documents

Publication Publication Date Title
JP2022543815A5 (cg-RX-API-DMAC7.html)
JP2022543612A5 (cg-RX-API-DMAC7.html)
JP2025172841A5 (cg-RX-API-DMAC7.html)
TWI633891B (zh) 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
JP2021112207A5 (cg-RX-API-DMAC7.html)
JP2022526738A5 (cg-RX-API-DMAC7.html)
JP2020523004A5 (cg-RX-API-DMAC7.html)
US20220220211A1 (en) Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
US20210148929A1 (en) Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
CN114173819A (zh) 通过施用il-4r拮抗剂治疗过敏和增强过敏原特异性免疫疗法的方法
RU2016136364A (ru) Способы лечения или предупреждения астмы посредством введения антагониста il-4r
JP2020100653A (ja) ベンラリツマブによる喘息症状の改善方法
JP2024532263A5 (cg-RX-API-DMAC7.html)
JP2025501239A5 (cg-RX-API-DMAC7.html)
WO2021255621A1 (en) Treatment of food allergy using anti-ige antibodies
JP2024544380A (ja) 抗IgE抗体を使用したアレルギー反応の治療
AU2021293980B2 (en) Treatment of food allergy using anti-IgE antibodies
RU2022105373A (ru) Способы лечения аллергии и усиления аллерген-специфической иммунотерапии путем введения антагониста il-4r
CN116887858A (zh) 通过施用il-4r拮抗剂治疗花生过敏并增强花生过敏原特异性免疫疗法的方法
NZ783048B2 (en) Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist
HK40016853A (en) Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
HK40016853B (en) Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
WO2026096637A1 (en) Glp-1 agonists and foralumab combination therapies
RU2022105374A (ru) Способы лечения атопического дерматита посредством введения антагониста il-4r
HK1226483B (en) Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)